Accelerated fractionation head and neck intensity-modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations
✍ Scribed by Alan T. Monroe; James A. Young; Jason D. Huff; Joel A. Ernster; Gerald A. White; Anuj V. Peddada
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 98 KB
- Volume
- 31
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity‐modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy.
Methods
Fifty‐two patients treated with IMRT at the Penrose Cancer Center between 2002 and 2007 constitute the cohort. The majority (75%) received an accelerated, altered fractionation regimen, typically concomitant boost to 7200 cGy. Concurrent chemotherapy was delivered to 32 (62%). The median follow‐up was 24 months.
Results
The 2‐year actuarial rates of local control, regional control, and distant metastasis–free survival were 100%, 91%, and 94%, respectively. Relapse‐free survival and overall survival at 2 years were 89% and 91%, respectively. Overall, 32 of 52 patients (62%) experienced at least 1 type of grade 3 or 4 acute toxicity.
Conclusion
Accelerated fractionation IMRT, with or without chemotherapy, can be given safely and effectively in a community cancer center setting. © 2009 Wiley Periodicals, Inc. Head Neck, 2009